The 21st Annual Industry/Academia Precision Oncology & RadMed Symposium will be held on Wednesday November 5, 2025

Thank you for your interest in the Symposium! We have closed Registration.

If you are interested in attending, please register onsite on November 5.

Questions? Please contact Leisa Sutton at lsutton(at)ucsd.edu.

Our Symposium site has the latest speaker list, talk titles, agenda, and updates.

Featured Presentations

• Session Chair, Eric Bennett, PhD, Professor, Department of Cell and Developmental Biology, UC San Diego
• Powering Early-Stage Drug Discovery with AI/ML & Community, Vanessa Braunstein, Senior Director, TuneLab AI Drug Discovery Platform, Lilly; Kathleen Lin, Senior Director, Site Head, Lilly Gateway Labs San Diego
• AI/ML for Forward/Reverse Translation, Jadwiga Bienkowska, PhD, Senior Director, Head of Computational Biology Oncology R&D, Pfizer
• Darlifarnib- bench to bedside development of a next-gen FTI in combination with cabozantinib in RCC, Francis Burrows, PhD, Chief Scientific Officer, Kura Oncology
• Expanding the scope of molecular glues into new targets and indications, Phil Chamberlain, DPhil, Co-Founder, President, and CEO, Neomorph
• ZBTB11 Depletion Targets Metabolic Vulnerabilities in K-Ras Inhibitor Resistant PDAC, Fleur Ferguson, PhD, Assistant Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego
• Omnimodal AI for Precision Oncology: Integrating Data to Drive Discovery, Nathan Fowler, MD, Chief Medical Officer, BostonGene Corporation
• AI Enables Rapid Identification of Targeted Cancer Therapy, Rick Fultz, Chief Executive Officer, Board Member, Acurion, Inc.
• DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma, Josep Garcia, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx; Katelyn Willis, PhD, Director, Biotherapeutics, Inhibrx
• HER3-Targeted Antibody-Drug Conjugates for IO Combination Therapy, J. Silvio Gutkind, PhD, Chair, Department of Pharmacology, Moores Cancer Center, UC San Diego
• Session Chair, Jake Haling, PhD, Head of Oncology Drug Discovery, San Diego, Novartis Institutes for Biomedical Research
• Session Chair, Analeah Heidt, PhD, Chief Scientific Officer, Enlaza Therapeutics
• Digital Tumors for Precision Oncology, Trey Ideker, PhD, Professor, Department of Medicine, Adjunct Professor, Departments of Bioengineering and Computer Science, UC San Diego
• AI-Guided Proteogenomics for Precision Oncology: Decoding Therapeutic Response in AML, Pilgrim Jackson, PhD, Chief Executive Officer, Yatiri Bio
• Session ChairShweta Joshi, PhD, Assistant Professor, Department of Pediatrics, Moores Cancer Center, UC San Diego
• Targeted alpha therapy with 212Pb, a short-lived isotope with long-lived benefit, Gary Li, PhD, Chief Strategy Officer, AdvanCell
• Advancing Novel Precision Oncology Therapeutics with Monovalent Targeted Protein Degraders, Michael Martin, PhD, Chief Executive Officer, Plexium
• From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery, Tom Miller, PhD, Co-Founder and CEO, Iambic Therapeutics
• AI-Based Automated Planning for Breast Radiotherapy: A Precision Individualized Approach, Lance Moore, MS, Quality, Innovation, Value, and Efficiency in Radiotherapy (QUIVER) Center, Radiation Medicine and Applied Sciences, UC San Diego
• Effects of radiopharmaceutical dose, isotope, and dose heterogeneity on anti-tumor immunity, Zachary Morris, MD, PhD, Associate Professor and Chair, Department of Human Oncology, University of Wisconsin-Madison
• Welcome Remarks, Arno J. Mundt, MD, FACRO, FASTRO, Professor and Founding Chair, Radiation Medicine and Applied Sciences, Executive Governing Committee, Moores Cancer Center, UC San Diego
• Session Chair, Sandip Patel, MD, Division of Hematology and Oncology, Department of Medicine, Moores Cancer Center, UC San Diego
• Session Chair, Paul Rejto, PhD, Vice President, Discovery Technologies, Pfizer
• Expanding Access to Radioligand Therapies: Reaching Every Patient, Everywhere, Brent Rose, MD, Associate Professor, Director, Division of Radiation Oncology, Co-Director, Center for Health Equity, Education and Research, Radiation Medicine and Applied Sciences, UC San Diego
• The landscape of opportunities for combining theranostics and radiotherapy in prostate cancer, Tyler Seibert, MD, PhD, Center for Precision Radiation Medicine, Radiation Medicine and Applied Sciences, UC San Diego
• Session Chair & Closing Remarks, Andrew Sharabi, MD, PhD, Professor & Jacobs Chancellor’s Endowed Chair in Radiation Medicine and Applied Sciences, Director, Center for Precision Radiation Medicine, Moores Cancer Cancer, UC San Diego
• The Proteostasis Network is a Therapeutic Target in Acute Myeloid Leukemia, Robert Signer, PhD, Deputy Director, Stem Cell Discovery Center, Associate Professor of Medicine, Division of Regenerative Medicine, Sanford Stem Cell Institute, UC San Diego
• Pioneering αRPT: Opportunities for Collaboration, Eileen Sneeden, PhD, Senior Director, Radiation Biophysics & Nuclear Oncology Liaison, RayzeBio, a Bristol Myers Squibb CompanyDuane Roth Achievement Award
• Evolution of Personalization and Precision Medicine in Radiation Oncology, Catheryn Yashar, MD, FACRO, FABS, FACR, FASTRO, Professor & Vice Chair of Clinical Affairs, Division of Radiation Oncology, Radiation Medicine and Applied Sciences, Chief Medical Officer, Health System, UC San Diego
• Targeting Tumor Microenvironment with Radioligands, Frederic Zecri, PhD, Chief Scientific Officer, Mariana Therapeutics, a Novartis company